Overcoming The 'Valley Of Death' For Cell And Gene Therapy Manufacturing


Any organization that has ever worked to bring a drug to market is familiar with the “valley of death” – for many nascent therapies, meeting clinical outcomes in time for the next funding cycle is the difference between progress and that so-called “death.” A therapy may have huge potential to address unmet need or improve on existing treatments, but without the money needed to support development, this potential is never realized.

Avoiding the valley of death requires an early understanding of a drug’s proposed development process, as well as the potential pitfalls that could stall that development. One of the most important decisions an organization can make early on relates to partnering. Selecting the right contract development and manufacturing organization (CDMO) to perform preclinical, clinical, and commercialization work can represent one of the most important decisions an organization can make in circumventing the valley of death and shepherding a therapy successfully to market.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene